CLINICAL TRIALS PROFILE FOR EXTAVIA
✉ Email this page to a colleague
All Clinical Trials for EXTAVIA
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01647880 ↗ | MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study) | Terminated | NeuroCure Clinical Research Center | Phase 2/Phase 3 | 2013-07-01 | In the MOVING study should be examined, whether early therapeutic intervention with fingolimod (Gilenya ®) after optic neuritis(ON) has a favorable visual outcome as a comparative therapie with Interferon beta-1b (Extavia®), as measured by multifocal visual evoked potentials (mVEP) after 6 month compared to baseline. |
NCT01647880 ↗ | MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study) | Terminated | NeuroCure Clinical Research Center, Charite, Berlin | Phase 2/Phase 3 | 2013-07-01 | In the MOVING study should be examined, whether early therapeutic intervention with fingolimod (Gilenya ®) after optic neuritis(ON) has a favorable visual outcome as a comparative therapie with Interferon beta-1b (Extavia®), as measured by multifocal visual evoked potentials (mVEP) after 6 month compared to baseline. |
NCT01647880 ↗ | MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study) | Terminated | Charite University, Berlin, Germany | Phase 2/Phase 3 | 2013-07-01 | In the MOVING study should be examined, whether early therapeutic intervention with fingolimod (Gilenya ®) after optic neuritis(ON) has a favorable visual outcome as a comparative therapie with Interferon beta-1b (Extavia®), as measured by multifocal visual evoked potentials (mVEP) after 6 month compared to baseline. |
NCT01466114 ↗ | Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition | Recruiting | Synthetic Biologics (formerly Adeona Pharmaceuticals) | Phase 2 | 2011-10-01 | Approximately 50% of people diagnosed with Multiple Sclerosis (MS) will develop problems with cognition. Currently, there are no FDA-approved treatments targeting cognitive function in Multiple Sclerosis. This trial will ascertain whether treatment with an estrogen pill, used in combination with standard MS anti-inflammatory drugs, can improve cognitive testing as compared to treatment with a placebo pill in combination with standard anti-inflammatory drugs in women with MS. |
NCT01466114 ↗ | Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition | Recruiting | University of California, Los Angeles | Phase 2 | 2011-10-01 | Approximately 50% of people diagnosed with Multiple Sclerosis (MS) will develop problems with cognition. Currently, there are no FDA-approved treatments targeting cognitive function in Multiple Sclerosis. This trial will ascertain whether treatment with an estrogen pill, used in combination with standard MS anti-inflammatory drugs, can improve cognitive testing as compared to treatment with a placebo pill in combination with standard anti-inflammatory drugs in women with MS. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for EXTAVIA
Condition Name
Clinical Trial Locations for EXTAVIA
Trials by Country
Clinical Trial Progress for EXTAVIA
Clinical Trial Phase
Clinical Trial Sponsors for EXTAVIA
Sponsor Name